Novartis Will Not Split Biosimilars From Sandoz As Part Of Review
Swiss Firm Focused On Carving Out Its Financials And Identifying Scope
Reporting Q4 and full-year earnings, Novartis told attendees to the company conference call that evaluating all options for its Sandoz business would take months yet, while making its position clear on Sandoz’ multi-billion-dollar biosimilars business.
You may also be interested in...
Sandoz: Big Cap Biosimilar Rivals Lack Clarity On Commitment
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.
Bourdage Becomes COO As Sandoz Shuffles Management
A management reshuffle at Sandoz has seen head of biopharmaceuticals Pierre Bourdage take on the role of chief operating officer among a number of changes, as parent company Novartis continues its strategic review of the generics and biosimilars unit.
Sandoz Says All Options Still Open After Spinoff Rumors
Sandoz has responded to recent rumors that parent company Novartis is favoring a spinoff of the generics and biosimilars business over a sale or retention, insisting that “all options remain open” as a strategic review of the unit continues.